266 related articles for article (PubMed ID: 36431851)
1. Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin.
Liu Q; Sun H; Li X; Sheng H; Zhu L
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431851
[TBL] [Abstract][Full Text] [Related]
2. Review targeted drug delivery systems for norcantharidin in cancer therapy.
Zhai BT; Sun J; Shi YJ; Zhang XF; Zou JB; Cheng JX; Fan Y; Guo DY; Tian H
J Nanobiotechnology; 2022 Dec; 20(1):509. PubMed ID: 36463199
[TBL] [Abstract][Full Text] [Related]
3. Formulation and evaluation of norcanthridin nanoemulsions against the Plutella xylostella (Lepidotera: Plutellidae).
Zeng L; Liu Y; Pan J; Liu X
BMC Biotechnol; 2019 Mar; 19(1):16. PubMed ID: 30871528
[TBL] [Abstract][Full Text] [Related]
4. Norcantharidin: research advances in pharmaceutical activities and derivatives in recent years.
Zhou J; Ren Y; Tan L; Song X; Wang M; Li Y; Cao Z; Guo C
Biomed Pharmacother; 2020 Nov; 131():110755. PubMed ID: 33152920
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro.
Yi SN; Wass J; Vincent P; Iland H
Leuk Res; 1991; 15(10):883-6. PubMed ID: 1921448
[TBL] [Abstract][Full Text] [Related]
6. Liposomal Nanodrug Based on Norcantharidin Derivative for Increased in Vivo Activity.
Kuang H; Wang P; Wang Y; Li J; Yu J; Jia L; Li S; Ma Y; Liu H; He Z; Wang Y
AAPS PharmSciTech; 2023 May; 24(5):118. PubMed ID: 37165275
[TBL] [Abstract][Full Text] [Related]
7. Unique Responses of Hepatocellular Carcinoma and Cholangiocarcinoma Cell Lines toward Cantharidin and Norcantharidin.
Ma Q; Feng Y; Deng K; Shao H; Sui T; Zhang X; Sun X; Jin L; Ma Z; Luo G
J Cancer; 2018; 9(12):2183-2190. PubMed ID: 29937938
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and anti-metastasis activities of norcantharidin-conjugated carboxymethyl chitosan as a novel drug delivery system.
Chi J; Jiang Z; Qiao J; Peng Y; Liu W; Han B
Carbohydr Polym; 2019 Jun; 214():80-89. PubMed ID: 30926011
[TBL] [Abstract][Full Text] [Related]
9. Supramolecular self-assembled AIE molecules are used in the search for target proteins in norcantharidin.
Ma L; Sun X; Ji W; Zhang B; Li J; Fu W; Zhang X; Qian W; Sheng E; Zhu D
Anal Chim Acta; 2023 Jan; 1239():340642. PubMed ID: 36628744
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of serine/threonine phosphatase inhibition by the archetypal small molecules cantharidin and norcantharidin.
Bertini I; Calderone V; Fragai M; Luchinat C; Talluri E
J Med Chem; 2009 Aug; 52(15):4838-43. PubMed ID: 19601647
[TBL] [Abstract][Full Text] [Related]
11. Norcantharidin modulates development of dendritic cells and prolongs skin allograft survival.
Hsieh CH; Liao HF; Kuo CD; Huang YC; Shueng PW; Hsu YP; Wang LY; Tsai TH; Chen YJ
Transplantation; 2011 Oct; 92(8):848-57. PubMed ID: 21876479
[TBL] [Abstract][Full Text] [Related]
12. Norcantharidin induces human melanoma A375-S2 cell apoptosis through mitochondrial and caspase pathways.
An WW; Wang MW; Tashiro S; Onodera S; Ikejima T
J Korean Med Sci; 2004 Aug; 19(4):560-6. PubMed ID: 15308848
[TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization and anticancer activity of norcantharidin-loaded poly(ethylene glycol)-poly(caprolactone) amphiphilic block copolymer micelles.
Chen SF; Lu WF; Wen ZY; Li Q; Chen JH
Pharmazie; 2012 Sep; 67(9):781-8. PubMed ID: 23016451
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro.
Fan YZ; Fu JY; Zhao ZM; Chen CQ
Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):72-80. PubMed ID: 17287171
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro cellular evaluation of novel anti-tumor norcantharidin-conjugated chitosan derivatives.
Xu X; Li Y; Shen Y; Guo S
Int J Biol Macromol; 2013 Nov; 62():418-25. PubMed ID: 24099934
[TBL] [Abstract][Full Text] [Related]
16. Primary in vitro and in vivo evaluation of norcantharidin-chitosan/poly (vinyl alcohol) for cancer treatment.
Li M; Xu X; Lu F; Guo S
Drug Deliv; 2014 Jun; 21(4):293-301. PubMed ID: 24156408
[TBL] [Abstract][Full Text] [Related]
17. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
18. Liquid chromatography-tandem mass spectrometry evaluation of the pharmacokinetics of a diacid metabolite of norcantharidin loaded in folic acid-targeted liposomes in mice.
Liu MC; Ma XQ; Xu Y; Peng LH; Han M; Gao JQ
J Pharm Biomed Anal; 2016 Feb; 119():76-83. PubMed ID: 26658337
[TBL] [Abstract][Full Text] [Related]
19. A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells.
Chen YJ; Chang WM; Liu YW; Lee CY; Jang YH; Kuo CD; Liao HF
Chem Biol Interact; 2009 Oct; 181(3):440-6. PubMed ID: 19616522
[TBL] [Abstract][Full Text] [Related]
20. Medical uses of mylabris in ancient China and recent studies.
Wang GS
J Ethnopharmacol; 1989 Sep; 26(2):147-62. PubMed ID: 2689797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
